Johnson & Johnson (JNJ) has faced many litigations over the years, the most serious of which being its faulty hip replacement system lawsuits.
Apart from bringing offshore cash back to the country, Trump also plans to encourage companies to relocate to the United States.
The semiconductor industry is a capital-intensive industry that spends a large amount of revenue on R&D (research and development) and capital expenditure.
About 82.0% of the analysts surveyed have rated Enbridge a “buy,” while 18.0% have rated it a “hold.”
On January 5, 2017, the Bad River Band of Lake Superior Chippewa called for the removal of Enbridge’s Line 5 pipeline from its reservation in Wisconsin.
On January 3, 2017, Marathon Petroleum (MPC) announced key initiatives related to its MLP MPLX (MPLX).
Verizon (VZ) is reviewing the impact of a fresh hack on the Yahoo! (YHOO) system that affected more than a billion accounts. Verizon agreed to acquire YHOO’s core assets for ~$4.8 billion, which could be renegotiated downward pending the outcome of the assessment of the hacking events.
From December 2014 to December 2016, Halliburton’s (HAL) stock price reached the highest level in December 2016. It troughed at ~$28 in January 2016.
On December 23, Halliburton (HAL) reached an agreement to settle a long-pending class action lawsuit. It will contribute $54 million to the settlement fund.
As part of the Inotera deal, Micron will also give Nanya the license to use its 1x and 1y DRAM technologies.
Alere (ALR) denied claims that any of the events that occurred during the last ten months would constitute any material change to the company’s value.
The merger deal between Abbott Laboratories (ABT) and Alere (ALR) has become an extended battle, and Wall Street analysts have been closely watching the ongoing developments in this deal.
On December 7, 2016, Scott Stoffel, divisional vice president of external communications at Abbott Laboratories, noted, “Alere is no longer the company Abbott agreed to buy 10 months ago.”
Abbott Laboratories (ABT) is focused on the strategic restructuring of its business while dealing with the acquisition difficulties with Alere.
Three months after announcing a $5.8 billion deal in which Abbott Laboratories (ABT) would buy Alere (ALR), Alere rejected Abbott’s $50 million offer to end the deal. On December 7, Abbott sued Alere to terminate the deal.
On November 22, 2016, Boston Scientific (BSX) announced the completion of its acquisition of EndoChoice Holdings. The deal was valued at $210 million in cash at a price of $8.00 per share.
On November 29, 2016, Nevro Corp. (NVRO) filed a lawsuit against Boston Scientific, claiming patent infringement on its patents for Senza and HF10 spinal cord stimulation therapies for chronic back pain.
Developed by Boston Scientific (BSX), HeartLogic is a system of sensors that can be attached to defibrillator devices. These sensors can monitor the patient and predict heart failure events.
Boston Scientific (BSX) stock has fallen ~7.4% since the release of the company’s 3Q16 earnings on October 26, 2016.
In a November 30 survey of 26 brokerage companies, ~81% of these analysts rated Boston Scientific (BSX) as a “buy” and 19% rated it as a “hold.” None of the analysts rated Boston Scientific as a “sell.”